Salisbury Foundation Trust


Internal Reference Number: FOI_5890

Date Request Received: 19/10/2020 13:58:35

Date Request Replied To: 27/10/2020 09:02:22

This response was sent via: By Email

Request Summary: biologic and biosimilar product prescribing in rheumatology

Request Category: Media

Question Number 1:
How many patients have been treated with biologics or biosimilar products in the last 12 months for the following conditions:
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Non-Radiographic Axial Spondyloarthritis
Answer To Question 1:
Rheumatoid Arthritis 487
Psoriatic Arthritis 172
Ankylosing Spondylitis 116
Non-Radiographic Axial Spondyloarthritis 5
Question Number 2:
Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 12 months with the following drugs.
• Abatacept [Orencia]
• Adalimumab [Amgevita]
• Adalimumab [Humira]
• Adalimumab [Hyrimoz]
• Adalimumab [Imraldi]
• Apremilast [Otezla]
• Baricitinib [Olumiant]
• Certolizumab [Cimzia]
• Etanercept [Benepali]
• Etanercept [Enbrel]
• Etanercept [Erelzi]
• Golimumab [Simponi]
• Infliximab [Flixabi]
• Infliximab [Inflectra]
• Infliximab [Remicade]
• Infliximab [Remsima]
• Ixekizumab [Taltz]
• Rituximab [MabThera]
• Rituximab [Rixathon]
• Rituximab [Truxima]
• Sarilumab [Kevzara]
• Secukinumab [Cosentyx]
• Tocilizumab [Ro Actemra]
• Tofacitinib [Xeljanz]
• Upadacitinib [Rinvoq]
• Ustekinumab [Stelara]
Answer To Question 2:
Abatacept [Orencia] 54
Adalimumab [Amgevita] 107
Adalimumab [Humira] 40
Adalimumab [Hyrimoz] 0
Adalimumab [Imraldi] 124
Apremilast [Otezla] 14
Baricitinib [Olumiant] 88
Certolizumab [Cimzia] 46
Etanercept [Benepali] 151
Etanercept [Enbrel] 11
Etanercept [Erelzi] 0
Golimumab [Simponi] 31
Infliximab [Flixabi] 0
Infliximab [Inflectra] 27
Infliximab [Remicade] 7
Infliximab [Remsima] 0
Ixekizumab [Taltz] 19
Rituximab [MabThera] 0
Rituximab [Rixathon] 0
Rituximab [Truxima] 65
Sarilumab [Kevzara] 1
Secukinumab [Cosentyx] 22
Tocilizumab [Ro Actemra] 59
Tofacitinib [Xeljanz] 51
Upadacitinib [Rinvoq] 0
Ustekinumab [Stelara] 9
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E:
© 2021 Salisbury NHS Foundation Trust
Trust Values